Creative Planning
AQST icon

Creative Planning’s Aquestive Therapeutics AQST Stock Holding History

Creative Planning’s Portfolio AQST Stock Details AQST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-7,500
Closed -$14K – 3075
2024
Q1 		$14K Buy
+7,500
New +$25K ﹤0.01% 2854

Other funds holding AQST

BCM
Bratton Capital Management Fort Worth, Texas $40.8M AUM 25.68% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

Creative Planning's AQST Position: Q2 2026 in Review

Creative Planning reduced its Aquestive Therapeutics (AQST) stake by 30% in Q2 2026, selling an estimated $233K and leaving 127,826 shares worth $532K. The position accounts for ﹤0.01% of the portfolio, ranked #3132.

Creative Planning first reported a position in AQST in Q1 2020 and has held it in 12 quarters since. The position peaked at $949K in Q4 2025. 185 funds tracked by Wall St. Rank hold AQST as of Q2 2026.

  • Creative Planning held 127,826 shares of Aquestive Therapeutics worth $532K as of Q2 2026.
  • Creative Planning sold 55,362 Aquestive Therapeutics shares in Q2 2026, an estimated $233K.
  • Aquestive Therapeutics made up ﹤0.01% of Creative Planning's portfolio in Q2 2026, its #3132 holding.
  • Creative Planning first reported a position in Aquestive Therapeutics in Q1 2020 and has held it in 12 quarters since.
  • Creative Planning's Aquestive Therapeutics position peaked at $949K in Q4 2025.
  • 185 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q2 2026.

Based on Creative Planning's 13F filing for Q2 2026, filed 13 Aug 2026.